Pharma Pulse 7/8/24: Moderna Awarded $176 Million, Palliative Care Strategies Can Improve the Management of Cardiovascular Disease & more

News
Article

The latest news for pharma industry insiders.

Moderna Awarded $176 Million from the Biomedical Advanced Research and Development Authority to Expedite Development of mRNA-Based Influenza Vaccines

Funding from the Biomedical Advanced Research and Development Authority (BARDA) is expected to support the late-stage development and licensure of a pre-pandemic vaccine targeting the H5 influenza virus.

Palliative Care Strategies Can Improve the Management of Cardiovascular Disease

Patients with cardiovascular disease (CVD) may benefit from palliative care therapy, according to the authors of a scientific statement from the American Heart Association (AHA) titled “Palliative Pharmacotherapy for Cardiovascular Disease.” Palliative care has a significant focus in medication management, shared decision-making, as well as goal-oriented care, which may provide patients with CVD relief from symptoms and enhanced quality-of-life.

New AI Technology Spurs Excitement and Concerns Among Private-Credit Managers

Unease about data bias and job security as the use of generative AI ramps up could temper enthusiasm among private lenders.

BenevolentAI: Leadership Team Change

BenevolentAI announced a change to its Executive Leadership Team following the recent Annual General Meeting and the election of a new Board of Directors.

@jakegoodmanmd on Threads

I’m a physician who treats mental health, and I just saw Inside Out 2.

Wow.

The way that they conceptualized anxiety was masterful. They showed that anxiety is NOT this scary villain who needs to be shunned from the rest of your emotions. Instead, anxiety keeps us safe and pushes us to plan for the future. Problems can arise when anxiety takes the wheel for too long, just like with any other emotion. I wish this movie existed when we were younger. 10/10.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs

© 2024 MJH Life Sciences

All rights reserved.